Food and Drug Administration (FDA) has approved Gilead Sciences’ hotly anticipated new hepatitis C virus (HCV) therapy Harvoni (ledipasvir/sofosbuvir)
[8] It is a fixed-dose combination of ledipasvir and sofosbuvir
HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is
The seroprevalence of the hepatitis C virus (HCV) in general population is higher than that of human immunodeficiency virus (HIV) in India
This systematic review evaluates the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) burden among people who inject drugs (PWIDs)
A new tool could change that
It is also the first approved regimen that does not require administration with interferon or ribavirin, two
It was approved in 2014
That said, drinking alcohol could worsen hepatitis C, which Harvoni is used to treat
Your child’s doctor will determine your child’s dosage based on their body weight in kilograms (kg)
12 weeks’ treatment, only if the person has a low risk of the disease getting worse
Harvoni (ledipasvir / sofosbuvir) is a combination medication containing two antiviral medications, ledipasvir and sofosbuvir (Sovaldi)
The price of other hepatitis C drugs is also high: Harvoni costs $94,500 for a 12-week treatment
Discuss monitoring for hepatitis B virus reactivation during HCV therapy
It is a combination of two antiviral medications
Sovaldi costs $1,000 a pill, or $84,000 for a typical 12-week course of treatment, but it must be used with other drugs
The cost of treatment with this drug can be high, and many people considering this course of treatment will need to know whether Medicaid covers Harvoni
Discuss the approach to retreatment of patients with chronic hepatitis C in the direct-acting antiviral (DAA) era
Sofosbuvir is an antiviral drug that is considered the “backbone” of hepatitis C treatment
HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: